Clinical Trial News and Research

RSS

Sirolimus may help treat lymphangioleiomyomatosis in women

An Oregon Health & Science University researcher has co-authored an international study that revealed a drug approved to prevent rejection in organ transplant patients helped treat a rare lung disease in women.

12 Apr 2011

Positive results from ULCA's Phase 1 dendritic cell vaccine trial in glioblastoma

A novel brain tumor vaccine clinical trial study demonstrates a longer survival time in patients with glioblastoma, according to findings being presented at the 79th Annual Scientific Meeting of the American Association of Neurological Surgeons in Denver.

12 Apr 2011

Novel drug holds potential against resistant chronic myeloid leukemia

A study from Tufts Medical Center researchers published today finds that a novel drug shows promise for treating leukemia patients who have few other options because their disease has developed resistance to standard treatment.

12 Apr 2011

Top-line results from DURECT's ELADUR Phase II trial in chronic low back pain

DURECT Corporation announced today top-line results from a Phase II clinical trial in chronic low back pain for ELADUR, DURECT's proprietary investigational transdermal bupivacaine pain patch.

12 Apr 2011

Epilepsy medication USL255 associated with less fluctuation in plasma levels compared to topiramate IR

Upsher-Smith Laboratories today announced the presentation of data indicating that once daily administration of USL255, a proprietary extended-release (ER) formulation of the epilepsy medication topiramate, was associated with less fluctuation in topiramate plasma levels compared to immediate-release (IR) topiramate administered twice daily in healthy volunteers.

12 Apr 2011

NCI awards MabVax with Phase II SBIR grant to develop vaccine against recurrent sarcoma

MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has received the Phase 2 portion of the Small Business Innovation Research Grant from the National Cancer Institute under the agency's Streamlined Non-competing Award Procedures.

11 Apr 2011

Positive interim results from PROLOR's hGH-CTP Phase II trial in growth hormone deficiency

PROLOR Biotech, Inc. today reported positive interim efficacy results from a Phase II clinical trial of its long-acting CTP-modified version of human growth hormone in growth hormone deficient adults.

11 Apr 2011

Positive top-line results from Biogen BG-12 Phase 3 trial in RRMS

Biogen Idec announced today positive top-line results from DEFINE, the first of two pivotal Phase 3 clinical trials designed to evaluate the investigational oral compound BG-12 as a monotherapy in people with relapsing-remitting multiple sclerosis.

11 Apr 2011

Study shows how specific nutritional combination may help maintain healthy breast tissue

Researchers from Canada and the United States today told attendees of the Experimental Biology 2011 Scientific Meeting that they have uncovered a possible means of enabling women to favorably influence whether the estrogens in their bodies take a "beneficial path" or a "disease-potential" path.

11 Apr 2011

Enigma initiates ML system trial in patients with influenza

Enigma Diagnostics announced today that it has commenced clinical trials for its intended point of care Enigma ML Influenza A/B detection assay. Enigma will submit its application to the U.S. Food and Drug Administration for approval of the assay in 2012.

11 Apr 2011

Research on rare cancers

A cancer diagnosis can be a life-changing event. Many questions arise, with one of the first being, "Where should I be treated?" Patients diagnosed with rare cancers may have difficulty finding a physician knowledgeable in treating their type of cancer.

11 Apr 2011

Synexus' Chief Medical Officer to discuss vaccine trial challenges at Washington event

Dr Glynis Neagle, Synexus' Chief Medical Officer will be discussing the challenges facing global vaccine trials at the World Vaccine Congress in Washington this week.

From AES - Accelerated Enrollment Solutions 11 Apr 2011

Annals of Neurology publishes Diamyd Medical´s NP2 Enkephalin Phase I results in cancer pain

Diamyd Medical´s Phase I clinical trial results evaluating the safety and efficacy of the candidate drug NP2 Enkephalin to treat intractable cancer pain has been published in the medical journal Annals of Neurology.

11 Apr 2011

New point-of-care trial can reduce cost and length of studies

Doctors at the Veterans Affairs Boston Healthcare System are testing a new kind of clinical trial that's not only less costly but guides doctors to switch to the best treatment even before the trial is completed.

11 Apr 2011

Merck announces interim analysis from V710 Phase II/III trial in S. aureus infection

Merck, known as MSD outside the United States and Canada, and Intercell AG today announced that following a pre-specified interim analysis from the Phase II/III clinical trial evaluating V710, an investigational vaccine for the prevention of Staphylococcus aureus infection, the independent Data Monitoring Committee recommended suspension of enrollment.

11 Apr 2011

Gilenya can reduce risk of disability progression in patients with RRMS

A new analysis demonstrated that Gilenya reduced the risk of disability progression in patients with relapsing-remitting multiple sclerosis, regardless of treatment history. This analysis of the phase III two-year FREEDOMS study is one of 11 abstracts on Gilenya being presented at the 63rd annual meeting of the American Academy of Neurology.

11 Apr 2011

Scientists identify new treatment to combat PFAPA syndrome in children

A preliminary study conducted by a team at the National Institutes of Health has identified a promising new treatment in children for the most common form of a rare disorder.

11 Apr 2011

IDSA, U.S. health officials describe ways to respond to global threat of antimicrobial resistance

To coincide with World Health Day on Thursday, the Infectious Diseases Society of America (IDSA) released a policy paper with nine recommendations for how to control the "ever-growing threat of antimicrobial resistance," CIDRAP News reports.

11 Apr 2011

Investigational drug effective for patients with obesity

An investigational combination of drugs already approved to treat obesity, migraine and epilepsy produced up to a 10 percent weight loss in obese individuals participating in a one-year clinical trial, according to researchers at Duke University Medical Center.

11 Apr 2011

FDA accepts Antares Pharma's Anturol NDA for filing, assigns PDUFA date

Antares Pharma, Inc. today announced the New Drug Application (NDA) for Anturol® Gel in patients with overactive bladder (OAB) was accepted for filing for review by the U.S. Food and Drug Administration (FDA). Anturol is an oxybutynin gel incorporating Antares' ATD Gel technology.

8 Apr 2011

Clinical Trial News and Research

Sirolimus may help treat lymphangioleiomyomatosis in women

Positive results from ULCA's Phase 1 dendritic cell vaccine trial in glioblastoma

Novel drug holds potential against resistant chronic myeloid leukemia

Top-line results from DURECT's ELADUR Phase II trial in chronic low back pain

Epilepsy medication USL255 associated with less fluctuation in plasma levels compared to topiramate IR

NCI awards MabVax with Phase II SBIR grant to develop vaccine against recurrent sarcoma

Positive interim results from PROLOR's hGH-CTP Phase II trial in growth hormone deficiency

Positive top-line results from Biogen BG-12 Phase 3 trial in RRMS

Study shows how specific nutritional combination may help maintain healthy breast tissue

Enigma initiates ML system trial in patients with influenza

Research on rare cancers

Synexus' Chief Medical Officer to discuss vaccine trial challenges at Washington event

Annals of Neurology publishes Diamyd Medical´s NP2 Enkephalin Phase I results in cancer pain

New point-of-care trial can reduce cost and length of studies

Merck announces interim analysis from V710 Phase II/III trial in S. aureus infection

Gilenya can reduce risk of disability progression in patients with RRMS

Scientists identify new treatment to combat PFAPA syndrome in children

IDSA, U.S. health officials describe ways to respond to global threat of antimicrobial resistance

Investigational drug effective for patients with obesity

FDA accepts Antares Pharma's Anturol NDA for filing, assigns PDUFA date

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News